Pegg, C. L., Cooper, L. T., Zhao, J., Gerometta, M., Smith, F. M., Yeh, M., . . . Boyd, A. W. (2017). Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist. Sci Rep.

Pegg, Cassandra L., Leanne T. Cooper, Jing Zhao, Michael Gerometta, Fiona M. Smith, Michael Yeh, Perry F. Bartlett, Jeffrey J. Gorman, and Andrew W. Boyd. "Glycoengineering of EphA4 Fc Leads to a Unique, Long-acting and Broad Spectrum, Eph Receptor Therapeutic Antagonist." Sci Rep 2017.

Pegg, Cassandra L., et al. "Glycoengineering of EphA4 Fc Leads to a Unique, Long-acting and Broad Spectrum, Eph Receptor Therapeutic Antagonist." Sci Rep 2017.